Search

Your search keyword '"G.G. Di Costanzo"' showing total 69 results
Start Over Author "G.G. Di Costanzo"
69 results on '"G.G. Di Costanzo"'

1. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Author

M. Rimini, L. Rimassa, K. Ueshima, V. Burgio, S. Shigeo, T. Tada, G. Suda, C. Yoo, J. Cheon, D.J. Pinato, S. Lonardi, M. Scartozzi, M. Iavarone, G.G. Di Costanzo, F. Marra, C. Soldà, E. Tamburini, F. Piscaglia, G. Masi, G. Cabibbo, F.G. Foschi, M. Silletta, T. Pressiani, N. Nishida, H. Iwamoto, N. Sakamoto, B.-Y. Ryoo, H.J. Chon, F. Claudia, T. Niizeki, T. Sho, B. Kang, A. D’Alessio, T. Kumada, A. Hiraoka, M. Hirooka, K. Kariyama, J. Tani, M. Atsukawa, K. Takaguchi, E. Itobayashi, S. Fukunishi, K. Tsuji, T. Ishikawa, K. Tajiri, H. Ochi, S. Yasuda, H. Toyoda, C. Ogawa, T. Nishimur, T. Hatanaka, S. Kakizaki, N. Shimada, K. Kawata, T. Tanaka, H. Ohama, K. Nouso, A. Morishita, A. Tsutsui, T. Nagano, N. Itokawa, T. Okubo, T. Arai, M. Imai, A. Naganuma, Y. Koizumi, S. Nakamura, K. Joko, H. Iijima, Y. Hiasa, F. Pedica, F. De Cobelli, F. Ratti, L. Aldrighetti, M. Kudo, S. Cascinu, A. Casadei-Gardini, M Rimini , L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, C Yoo, J Cheon, D J Pinato, S Lonardi, M Scartozzi, M Iavarone, G G Di Costanzo, F Marra, C Soldà, E Tamburini, F Piscaglia, G Masi, G Cabibbo, F G Foschi, M Silletta, T Pressiani, N Nishida, H Iwamoto, N Sakamoto, B-Y Ryoo, H J Chon, F Claudia, T Niizeki, T Sho, B Kang, A D'Alessio, T Kumada, A Hiraoka, M Hirooka, K Kariyama, J Tani, M Atsukawa, K Takaguchi, E Itobayashi, S Fukunishi, K Tsuji, T Ishikawa, K Tajiri, H Ochi, S Yasuda, H Toyoda, C Ogawa, T Nishimur, T Hatanaka, S Kakizaki, N Shimada, K Kawata , T Tanaka, H Ohama, K Nouso, A Morishita, A Tsutsui, T Nagano, N Itokawa, T Okubo, T Arai, M Imai, A Naganuma, Y Koizumi, S Nakamura, K Joko, H Iijima, Y Hiasa, F Pedica, F De Cobelli, F Ratti, L Aldrighetti, M Kudo, S Cascinu, A Casadei-Gardini, Rimini M., Rimassa L., Ueshima K., Burgio V., Shigeo S., Tada T., Suda G., Yoo C., Cheon J., Pinato D.J., Lonardi S., Scartozzi M., Iavarone M., Di Costanzo G.G., Marra F., Solda C., Tamburini E., Piscaglia F., Masi G., Cabibbo G., Foschi F.G., Silletta M., Pressiani T., Nishida N., Iwamoto H., Sakamoto N., Ryoo B.-Y., Chon H.J., Claudia F., Niizeki T., Sho T., Kang B., D'Alessio A., Kumada T., Hiraoka A., Hirooka M., Kariyama K., Tani J., Atsukawa M., Takaguchi K., Itobayashi E., Fukunishi S., Tsuji K., Ishikawa T., Tajiri K., Ochi H., Yasuda S., Toyoda H., Ogawa C., Nishimur T., Hatanaka T., Kakizaki S., Shimada N., Kawata K., Tanaka T., Ohama H., Nouso K., Morishita A., Tsutsui A., Nagano T., Itokawa N., Okubo T., Arai T., Imai M., Naganuma A., Koizumi Y., Nakamura S., Joko K., Iijima H., Hiasa Y., Pedica F., De Cobelli F., Ratti F., Alrighetti L., Kudo M., Cascinu S., and Casadei-Gardini A.

Subjects
atezolizumab, Cancer Research, Settore MED/12 - Gastroenterologia, Oncology, sorafenib, NAFLD, NASH, advanced HCC, advanced HCC, NASH, NAFLD, lenvatinib, sorafenib, atezolizumab, bevacizumab, lenvatinib, bevacizumab
Abstract

Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and methods: We carried out a retrospective analysis of prospectively collected data from consecutive patients with non-viral advanced HCC, treated with atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers in 4 countries (Italy, Japan, Republic of Korea, and UK). The primary endpoint was overall survival (OS) with atezolizumab plus bevacizumab versus lenvatinib. Secondary endpoints were progression-free survival (PFS) with atezolizumab plus bevacizumab versus lenvatinib, and OS and PFS with atezolizumab plus bevacizumab versus sorafenib. For the primary and secondary endpoints, we carried out the analysis on the whole population first, and then we divided the cohort into two groups: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) population and non-NAFLD/NASH population. Results: One hundred and ninety patients received atezolizumab plus bevacizumab, 569 patients received lenvatinib, and 210 patients received sorafenib. In the whole population, multivariate analysis showed that treatment with lenvatinib was associated with a longer OS [hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.44-0.95; P = 0.0268] and PFS (HR 0.67; 95% CI 0.51-0.86; P = 0.002) compared to atezolizumab plus bevacizumab. In the NAFLD/NASH population, multivariate analysis confirmed that lenvatinib treatment was associated with a longer OS (HR 0.46; 95% CI 0.26-0.84; P = 0.0110) and PFS (HR 0.55; 95% CI 0.38-0.82; P = 0.031) compared to atezolizumab plus bevacizumab. In the subgroup of non-NAFLD/NASH patients, no difference in OS or PFS was observed between patients treated with lenvatinib and those treated with atezolizumab plus bevacizumab. All these results were confirmed following propensity score matching analysis. By comparing patients receiving atezolizumab plus bevacizumab versus sorafenib, no statistically significant difference in survival was observed. Conclusions: The present analysis conducted on a large number of advanced non-viral HCC patients showed for the first time that treatment with lenvatinib is associated with a significant survival benefit compared to atezolizumab plus bevacizumab, in particular in patients with NAFLD/NASH-related HCC.

Published
2022

3. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

Author

Marianna Silletta, V. Burgio, Gianluca Masi, A. Takata, M.G. Viola, Mario Domenico Rizzato, Kazuto Tajiri, H. Toyoda, M. Scartozzi, Francesca Salani, Syusuke Okamura, Francesco Giuseppe Foschi, Takashi Kumada, G. Astara, I.G. Rapposelli, Fabio Conti, Emiliano Tamburini, Claudia Campani, Kazuhito Kawata, Fabio Marra, A. Forgione, A. Hiraoka, Giovanni Luca Frassineti, R. Tortora, Takuji Torimura, Shigeo Shimose, Masahito Nakano, Masanori Atsukawa, Stefano Cascinu, Andrea Casadei-Gardini, H. Shibata, G.G. Di Costanzo, Caterina Vivaldi, Antonio Pellino, Claudia Angela Maria Fulgenzi, Toshifumi Tada, Eleonora Lai, Fabio Piscaglia, S. Lonardi, Margherita Rimini, Rapposelli, I. G., Shimose, S., Kumada, T., Okamura, S., Hiraoka, A., Di Costanzo, G. G., Marra, F., Tamburini, E., Forgione, A., Foschi, F. G., Silletta, M., Lonardi, S., Masi, G., Scartozzi, M., Nakano, M., Shibata, H., Kawata, K., Pellino, A., Vivaldi, C., Lai, E., Takata, A., Tajiri, K., Toyoda, H., Tortora, R., Campani, C., Viola, M. G., Piscaglia, F., Conti, F., Fulgenzi, C. A. M., Frassineti, G. L., Rizzato, M. D., Salani, F., Astara, G., Torimura, T., Atsukawa, M., Tada, T., Burgio, V., Rimini, M., Cascinu, S., Casadei-Gardini, A., Rapposelli I.G., Shimose S., Kumada T., Okamura S., Hiraoka A., Di Costanzo G.G., Marra F., Tamburini E., Forgione A., Foschi F.G., Silletta M., Lonardi S., Masi G., Scartozzi M., Nakano M., Shibata H., Kawata K., Pellino A., Vivaldi C., Lai E., Takata A., Tajiri K., Toyoda H., Tortora R., Campani C., Viola M.G., Piscaglia F., Conti F., Fulgenzi C.A.M., Frassineti G.L., Rizzato M.D., Salani F., Astara G., Torimura T., Atsukawa M., Tada T., Burgio V., Rimini M., Cascinu S., and Casadei-Gardini A.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, lenvatinib prognostic index, Carcinoma, Hepatocellular, hepatocellular carcinoma, recursive partitioning analysis, Humans, Phenylurea Compounds, Prognosis, Quinolines, Chemoembolization, Therapeutic, Liver Neoplasms, Recursive partitioning, Prognostic score, chemistry.chemical_compound, Internal medicine, medicine, Original Research, business.industry, Carcinoma, Treatment options, Hepatocellular, medicine.disease, chemistry, Hepatocellular carcinoma, Cohort, Chemoembolization, Therapeutic, Medium Risk, Lenvatinib, business
Abstract

Background After the advent of new treatment options for advanced hepatocellular carcinoma (HCC), the identification of prognostic factors is crucial for the selection of the most appropriate therapy for each patient. Patients and methods With the aim to fill this gap, we applied recursive partitioning analysis (RPA) to a cohort of 404 patients treated with lenvatinib. Results The application of RPA resulted in a classification based on five variables that originated a new prognostic score, the lenvatinib prognostic index (LEP) index, identifying three groups: low risk [patients with prognostic nutritional index (PNI) >43.3 and previous trans-arterial chemoembolization (TACE)]; medium risk [patients with PNI >43.3 but without previous TACE and patients with PNI, Highlights • This study shows a new prognostic index (LEP index) for patients undergoing systemic therapy for hepatocellular carcinoma. • LEP index is an easy-to-use tool, based on clinical and laboratory features, that identifies three risk groups. • LEP index may be used to stratify hepatocellular carcinoma patients in order to select the most appropriate treatment.

Published
2021

4. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study

Author

M. Rendina, M. Barone, S. Trapani, L. Masiero, P. Trerotoli, F. Puoti, L.G. Lupo, S. Agnes, A. Grieco, E. Andorno, S. Marenco, U. Baccarani, P. Toniutto, A. Carraro, A. Colecchia, M. Cescon, M.C. Morelli, U. Cillo, P. Burra, P. Angeli, M. Colledan, S. Fagiuoli, L. De Carlis, L. Belli, P. De Simone, P. Carrai, F. Di Benedetto, N. De Maria, G.M. Ettorre, V. Giannelli, S. Gruttadauria, R. Volpes, V. Mazzaferro, S. Bhoori, R. Romagnoli, S. Martini, G. Rossi, F. Donato, M. Rossi, S. Ginanni Corradini, M. Spada, G. Maggiore, G. Tisone, I. Lenci, G. Vennarecci, G.G. Di Costanzo, M. Vivarelli, G. Svegliati Baroni, F. o Zamboni, L. Mameli, S. Tafuri, S. Simone, L. Gesualdo, M. Cardillo, and A. Di Leo

Subjects
Hepatology, Gastroenterology
Published
2022

5. Psychological profiles and risk of relapse in cirrhosis due to alcohol abuse

Author

D. Ferraro, I. Esposito, Antonio Ceriello, D. Pisaniello, A. Cangiano, F. Giordano, Carla Migliaccio, F.P. Picciotto, G.G. Di Costanzo, V.G.M. Moreas, G. Arenga, G. Aragiusto, A. Galeota Lanza, G. Mazzarone, C. Chierego, Ciro Esposito, L. Campanella, and Giovanni Vennarecci

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, Alcohol abuse, Relapse risk, business, medicine.disease
Published
2021

6. AF.93 COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIAN CASE-CONTROL DOUBLE-CENTER STUDY

Author

Michele Pier Luca Guarino, M. Capasso, V. Cozza, L. De Coppi, Valentina Cossiga, Ilaria Loperto, F.P. Picciotto, R. Ortolani, I. Esposito, Giuseppina Pontillo, Andrea Fiorentino, Filomena Morisco, G.G. Di Costanzo, and L. Pignata

Subjects
2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, Hepatology, Coronavirus disease 2019 (COVID-19), Liver, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, medicine, Center (algebra and category theory), business, Abstracts of the 27th National Congress of Digestive Diseases 2021 – FISMAD
Published
2021

7. Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model

Author

Rodolfo Sacco, T. Pressiani, Alessandro Granito, R. Tortora, G.G. Di Costanzo, Franco Trevisani, Vito Sansone, Francesco Tovoli, Luca Ielasi, Andrea Casadei-Gardini, and Giulia Magini

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, External validation, business, medicine.disease, medicine.drug
Published
2020

8. Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study

Author

Salvatore Gruttadauria, Marco Vivarelli, Fausto Zamboni, S. Ginanni Corradini, L. Lupo, Silvia Martini, L. De Carlis, Stefano Fagiuoli, Ilaria Lenci, Giuseppe Valerio Bianco, Lino Belli, P De Simone, W. Santaniello, Gabriele Spoletini, Pierluigi Toniutto, Renato Romagnoli, L. Mameli, Matteo Cescon, Valerio Giannelli, Michele Colledan, A.W. Avolio, Antonio Benedetti, Quirino Lai, Riccardo Volpes, G.G. Di Costanzo, Giuseppe Maria Ettorre, U Tedeschi, G. Tisone, A. Grieco, Amedeo Carraro, Sherrie Bhoori, Salvatore Agnes, Paola Carrai, Francesco Donato, U. Cillo, P. Burra, A Franco, Andrea Risaliti, Gemma Rossi, V. Nobile, F. Di Benedetto, C. Donato, R. Calia, Marcos A. Rossi, M. Rendina, Marco Spada, Vincenzo Mazzaferro, N. De Maria, Avolio, A, Lai, Q, Franco, A, Bianco, G, Calia, R, Spoletini, G, Agnes, S, Grieco, A, Rossi, M, Corradini, S, Vivarelli, M, Benedetti, A, Lupo, L, Rendina, M, Colledan, M, Fagiuoli, S, Cescon, M, Donato, C, Zamboni, F, Mameli, L, De Carlis, L, Belli, L, Rossi, G, Donato, F, Mazzaferro, V, Bhoori, S, Di Benedetto, F, De Maria, N, Santaniello, W, Di Costanzo, G, Gruttadauria, S, Volpes, R, De Simone, P, Carrai, P, Spada, M, Nobile, V, Ettorre, G, Giannelli, V, Tisone, G, Lenci, I, Romagnoli, R, Martini, S, Risaliti, A, Toniutto, P, Tedeschi, U, Carraro, A, Burra, P, and Cillo, U

Subjects
Pediatrics, medicine.medical_specialty, Case mix index, Hepatology, liver transplantation, business.industry, medicine.medical_treatment, Gastroenterology, medicine, Patient survival, Liver transplantation, business
Published
2019

9. Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation

Author

M. Romero Cristóbal, Marcus-Alexander Wörns, R. Prince, L. Scuddeler, G. Sapisochin, M.L. González-Diéguez, Claudio Zavaglia, Helene Regnault, Maria Margarita Anders, Federica Invernizzi, Jordi Bruix, Giuliana Amaddeo, Lucia Cesarini, M. Reig, Álvaro Díaz-González, Matteo Angelo Manini, Matthias Pinter, Marco Sanduzzi-Zamparelli, M. Fraile-López, R. Tortora, Tommy Ivanics, Stefano Mazza, P. Daechul Yoon, Maria Francesca Donato, M.J. Blanco Rodríguez, Vincenzo Mazzaferro, Federico Piñero, M. Varela, Carolin Czauderna, Gonzalo Crespo, A. Fernandez Yunquera, Gerda Elisabeth Villadsen, Massimo Iavarone, G. Aballay Soteras, M. De Giorgio, Pietro Lampertico, G.G. Di Costanzo, Sherrie Bhoori, and Arndt Weinmann

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Liver transplantation, chemistry.chemical_compound, chemistry, Regorafenib, Internal medicine, medicine, In patient, business, medicine.drug
Published
2021

11. P.04.14 HEPATOCELLULAR CARCINOMA AND SMOKING ARE INDEPENDENT RISK FACTORS FOR DEVELOPMENT OF DE-NOVO EXTRAHEPATIC TUMORS IN LIVER TRANSPLANT RECIPIENTS

Author

Luigi Addario, M. De Luca, A. Telese, A. Galeota Lanza, M.T. Tartaglione, F. Lampasi, W. Santaniello, Luigi Gaeta, G.G. Di Costanzo, F.P. Picciotto, G. Cordone, and R. Tortora

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, business, medicine.disease
Published
2019

12. OC.07.4 HCC RECURRENCE AFTER DAA TREATMENT IN HCV PATIENTS

Author

Federica Morando, Nicola Coppola, Filomena Morisco, Luca Rinaldi, Michele Pier Luca Guarino, Marco Guarracino, A. Salomone Megna, Nicola Caporaso, G.G. Di Costanzo, Marcello Persico, Dario Bruzzese, and Anna Sessa

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published
2019

13. Safety and Efficacy of Subcutaneous Hepatitis B Immunoglobulin After Liver Transplantation: An Open Single-Arm Prospective Study

Author

Alfonso Galeota Lanza, M. De Luca, G. Cordone, G.G. Di Costanzo, Michele Imparato, Carla Migliaccio, R. Tortora, F. Calise, Vincenzo Scuderi, Wanda Utech, and F.P. Picciotto

Subjects
Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, medicine.medical_treatment, Immunoglobulins, Self Administration, Liver transplantation, medicine.disease_cause, Antiviral Agents, Gastroenterology, Cohort Studies, Internal medicine, medicine, Humans, Immunology and Allergy, Pharmacology (medical), Prospective Studies, Prospective cohort study, Aged, Hepatitis B virus, Transplantation, business.industry, Middle Aged, Hepatitis B, Hepatitis B immunoglobulin, Liver Transplantation, Surgery, Clinical trial, Titer, Treatment Outcome, Lamivudine, Quality of Life, Female, Self-administration, business, Cohort study
Abstract

Life-long hepatitis B immunoglobulin (HBIG) administration is a main component of prophylactic strategy to prevent hepatitis B virus (HBV) reinfection after liver transplantation (LT). Long-term effects of HBIG treatment are known only for intravenous (IV) and intramuscular formulations. To evaluate safety and efficacy of self-administered SC HBIG, 135 LT patients receiving a 48-week treatment were analyzed. The dose of HBIG was 500 IU or 1000 IU if body weight was75 kg or ≥75 kg, respectively. Patients were switched from the monthly IV HBIG treatment to weekly SC HBIG 2-3 weeks after the last IV dosage. All patients were able to SC self-injection after a single training. The treatment was effective in maintaining trough anti-HBs levels100 IU/L. No severe drug-related side effects occurred. Fifteen injection-site small hematomas and four cases of mild itch occurred. At the end of the study, anti-HBs median titer was 232 IU/L (115-566 IU/L) and 97.8% of patients had an anti-HBs level150 IU/L. Due to high mean level of anti-HBs titers observed during this study, individualized treatment schedules should be further investigated. In conclusion, SC HBIG for long-term prophylaxis of post-LT HBV reinfection resulted safe, well accepted, and effective in maintaining adequate anti-HBs levels.

Published
2013

15. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma

Author

M. Scartozzi, G. Cordone, Vincenzo Palmieri, Luca Faloppi, R. Tortora, G. Ercoloani, G.G. Di Costanzo, N. Silvestris, Stefano Cascinu, Giorgia Marisi, Francesco Giuseppe Foschi, R. Granata, A. Casadei Gardini, and Oronzo Brunetti

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Scoring system, Hepatology, business.industry, Gastroenterology, medicine.disease, Simple (abstract algebra), Hepatocellular carcinoma, Internal medicine, medicine, In patient, business, medicine.drug
Published
2017

16. HCC recurrence after DAA treatment in HCV patients

Author

Nicola Coppola, Filomena Morisco, Nicola Caporaso, Luca Rinaldi, Federica Morando, G.G. Di Costanzo, A. Salomone Megna, Michele Pier Luca Guarino, Marco Guarracino, Marcello Persico, and Dario Bruzzese

Subjects
03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, 030211 gastroenterology & hepatology, business, 030226 pharmacology & pharmacy
Published
2018

17. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: A pilot study

Author

Charlotte K.Y. Ng, Cristina Quintavalle, Markus H. Heim, Stefan Wieland, Matthias S. Matter, Salvatore Piscuoglio, G. Marino-Marsilia, Giuseppina Roscigno, R. Tortora, Viola Paradiso, Marco Guarracino, Manuela Lanzafame, T. Boldanova, Mairene Coto-Llerena, Luca Quagliata, Valeria Perrina, G.G. Di Costanzo, Nadia Tosti, Gerolama Condorelli, and L. Terracciano

Subjects
0301 basic medicine, Hepatology, business.industry, Plasma derived, Gastroenterology, medicine.disease, Therapy naive, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, DNA profiling, Cell-free fetal DNA, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Cancer research, medicine, business
Published
2018

18. The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer

Author

Elena Fea, Ida Colantonio, Ornella Garrone, G. Cento, G.G. Di Costanzo, Elvio G. Russi, Gianmauro Numico, Gianfilippo Bertelli, Milena Gasco, Cristina Granetto, Marco Merlano, M. Anfossi, Nicola Silvestris, and Marcella Occelli

Subjects
Adult, Male, Health Knowledge, Attitudes, Practice, medicine.medical_specialty, Palliative care, Adolescent, Referral, Attitude of Health Personnel, Medical Oncology, Truth Disclosure, Young Adult, Level of consciousness, Patient Education as Topic, Neoplasms, Surveys and Questionnaires, medicine, Humans, In patient, Referral and Consultation, Aged, Aged, 80 and over, Physician-Patient Relations, business.industry, Age Factors, Cancer, Hematology, Awareness, Middle Aged, Prognosis, medicine.disease, Surgery, Patient Rights, Oncology, Health Care Surveys, Family medicine, Workforce, Female, Empathy, Communication skills, Comprehension, Training program, business, Program Evaluation
Abstract

Surveys carried out in Mediterranean countries demonstrated very low rates of awareness of both diagnosis and prognosis among cancer patients. In our institution, a long-term training program aimed at improving communication skills among all physicians interacting with cancer patients was conducted. We report here the results of an extensive assessment of patients' awareness conducted after the first training period.In a 2-year period, after every first visit of patients with a histological diagnosis of cancer, oncologists elicited perception of the patients and completed a structured questionnaire focusing on the understanding of the diagnosis and prognosis. Our data are thus a photograph of the results of the informative process conducted during the diagnostic phase.Among the enrolled 649 patients, 79.3% were aware of their diagnosis; factors significantly associated with higher levels of awareness were age younger than 70 and referral from surgery (versus internal medicine). Knowledge about the palliative or curative aims of future treatments (a surrogate sign of prognostic consciousness) was evident in 55.2%.Compared with historical data, our results show a high level of comprehension of the diagnosis of malignancy, probably due to the extensive training effort together with the method chosen for assessment.

Published
2009

19. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC)

Author

P. Giovanis, S. D'Angelo, Mario Pirisi, G. de Stefano, Adolfo Francesco Attili, D. Sansonno, Antonio Benedetti, T. Zolfino, Salvatore Pisconti, Giuseppe Cabibbo, Lydia Giannitrapani, Bruno Daniele, Vito Lorusso, M. Moscovici, Rodolfo Sacco, Vincenzo Montesarchio, P. Carucci, G.G. Di Costanzo, F. De Vita, and Angela Buonadonna

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Clinical Practice, Pooled analysis, Hepatocellular carcinoma, Internal medicine, medicine, Observational study, business, medicine.drug
Published
2016

20. P.09.7: Mucosal GUT Microbiota Composition in Patients with HCV Infection, from Chronic Hepatitis to Hepatocellular Carcinoma

Author

Pietro Coccoli, V. Precone, Domenica Lovero, V. D’Argenio, G.G. Di Costanzo, S. Saviano, Alice Di Rocco, Gerardo Nardone, Debora Compare, Graziano Pesole, M. Sanduzzi Zamparelli, Mauro Esposito, G. Casaburi, Bruno Fosso, I. Postiglione, and Francesco Salvatore

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Gut flora, medicine.disease, biology.organism_classification, Chronic hepatitis, Internal medicine, Hepatocellular carcinoma, Medicine, In patient, business
Published
2017

22. Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience

Author

Michele Pier Luca Guarino, R. Tortora, G. Cordone, M.S. Zamparelli, G.G. Di Costanzo, and R. Granata

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Single Center, Gastroenterology, Virology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Hepatocellular carcinoma, medicine, 030211 gastroenterology & hepatology, business
Published
2017

23. Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)

Author

Anna Maria Vandone, Marcella Occelli, Nerina Denaro, Ornella Garrone, Emanuela Miraglio, Vincenzo Ricci, Elena Fea, Paola Vanella, G.G. Di Costanzo, Cristina Granetto, I. Colantonio, Carolina Cauchi, and Marco Merlano

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Hematology, Castration resistant, medicine.disease, 03 medical and health sciences, Prostate cancer, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Oral cyclophosphamide, business
Published
2016

26. Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania

Author

Le Adinolfi, G. de Stefano, G. Nardone, G. Francica, Guido Piai, Francesco Izzo, Giuseppe D'Adamo, S.M. Angelo, Carmine Coppola, Michele Pier Luca Guarino, V. De Girolamo, G.B. Gaeta, Nicola Coppola, Vincenzo Messina, R. Tortora, G.G. Di Costanzo, and Filomena Morisco

Subjects
medicine.medical_specialty, Hepatology, Field practice, business.industry, Family medicine, Medicine, business
Published
2016

29. Serum level of SCCA-IgM are related to the efficacy of HCC treatments

Author

MORISCO, FILOMENA, M. GAURINO, R. TORTORA, L. DONNARUMMA, I. LOPERTO, S. CAMERA, A. MARINIELLO, C. TUCCILLO, L. BENEDUCE, G.G. DI COSTANZO, CAPORASO, NICOLA, Morisco, Filomena, M., Gaurino, R., Tortora, L., Donnarumma, I., Loperto, S., Camera, A., Mariniello, C., Tuccillo, L., Beneduce, DI COSTANZO, G. G., and Caporaso, Nicola

Published
2012

30. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy

Author

Carmine Coppola, Filomena Morisco, S. Camera, G.G. Di Costanzo, Alessandro Federico, Ernesto Claar, Davide F Precone, Marcello Persico, A. De Luna, A. Salomone Megna, Mario Masarone, R. Granata, Nicola Coppola, Valerio Rosato, and Ivan Gentile

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine, business, Intensive care medicine, Real life data, Telaprevir, medicine.drug
Published
2014

31. P.17.10 ADHERENCE TO TRIPLE THERAPY IN HCV

Author

Nicola Caporaso, Michele Pier Luca Guarino, S. Camera, G.G. Di Costanzo, F. Lampasi, R. Granata, Valentina Cossiga, M.T. Tartaglione, Ilaria Loperto, Filomena Morisco, C. Ferraiuoli, and E. Clery

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, business
Published
2014

32. Safety and efficacy of sorafenib in stella study, a Multicenter, Observational, Phase IV Study In Italian Centers

Author

T. Fontana, F. De Vita, Rodolfo Sacco, P. Carucci, C. Erminero, G. de Stefano, P. Giovanis, G.G. Di Costanzo, Adolfo Francesco Attili, T. Zolfino, Salvatore Pisconti, Vincenzo Montesarchio, Bruno Daniele, and Giuseppe Cabibbo

Subjects
Oncology, Sorafenib, medicine.medical_specialty, business.industry, Internal medicine, Medicine, STELLA (programming language), Observational study, Hematology, business, medicine.drug
Published
2015

33. P0369 : Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients

Author

Concetta Tuccillo, R. Granata, Francesco Auriemma, Nicola Caporaso, Filomena Morisco, G.G. Di Costanzo, Ilaria Loperto, Andrea Gallotta, Maria Guarino, R. Tortora, and Giorgio Fassina

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.disease, Lower risk, Gastroenterology, MERTK Gene, Liver disease, Internal medicine, Genotype, medicine, Biomarker (medicine), SNP, business
Abstract

s / Digestive and Liver Disease 46S (2014) e136–e141 e137 all 248 patients had reached HBV undetectability

Published
2015

34. P.18.23 SCCA-IgM: A BIOMARKER TO MONITOR THE OUTCOME OF THERAPY WITH SORAFENIB IN ADVANCED HCC

Author

Nicola Caporaso, Francesco Auriemma, R. Tortora, Michele Pier Luca Guarino, C. Ferraiuoli, Ilaria Loperto, L. Beneduce, Concetta Tuccillo, Filomena Morisco, and G.G. Di Costanzo

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Biomarker (medicine), business, medicine.drug
Published
2013

35. 524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS

Author

G.G. Di Costanzo, A. Caputo, María Isabel Colombo, Mauro Viganò, Tiziana Giuberti, Patrizia Farci, Fabio Facchetti, Silvia Fargion, Evangelista Sagnelli, Pietro Lampertico, Loredana Regep, S. Boninsegna, Massimo Fasano, Vivien Rothe, and V. Di Marco

Subjects
medicine.medical_specialty, HBsAg, Hepatology, Hbeag negative, business.industry, Internal medicine, Genotype, medicine, business, Gastroenterology, Peginterferon alfa-2a, medicine.drug
Published
2012

36. F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance

Author

G.G. Di Costanzo, T. Santantonio, Evangelista Sagnelli, S. Pierconti, Giuseppe Mazzella, Vincenzo Messina, Pietro Lampertico, Mario Angelico, L. Cimino, Gianluca Brancaccio, Grazia Anna Niro, G. Raimondo, G.B. Gaeta, Stefano Fagiuoli, Mauro Viganò, M. Puoti, Massimo Levrero, Miroslava Subic, Angelo V. Marzano, V. Di Marco, and C. Sava

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Internal medicine, Gastroenterology, medicine, Prospective cohort study, business, medicine.drug
Published
2011

44. 194 ANTI-HBV IMMUNOPROPHYLAXIS IN LIVER TRANSPLANTED PATIENTS USING SUBCUTANEOUS ADMINISTRATION OF HBIG: PRELIMINARY RESULTS OF AN ONGOING OBSERVATIONAL STUDY

Author

Carla Migliaccio, A. Galeota Lanza, F. Calise, Michele Imparato, G.G. Di Costanzo, M. Romano, Antonio Giuliani, F.P. Picciotto, and Giuseppe Surfaro

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, Observational study, Intensive care medicine, business, Administration (government), Anti hbv
Published
2012

45. P.08.2 SERUM LEVELS OF SCCA-IGM ARE RELATED TO THE EFFICACY OF HCC TREATMENTS

Author

Filomena Morisco, A. Mariniello, G.G. Di Costanzo, R. Tortora, Nicola Caporaso, S. Camera, Concetta Tuccillo, Ilaria Loperto, L. Beneduce, Michele Pier Luca Guarino, and L. Donnarumma

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published
2012

48. P.1.97: SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA: EFFECTIVENESS AND IMPACT OF ADVERSE EFFECTS IN DAILY CLINICAL PRACTICE

Author

M. De Luca, A. Galeota Lanza, G.G. Di Costanzo, R. Pacilio, R. Tortora, M.T. Tartaglione, and F. Lampasi

Subjects
Oncology, medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Colorectal cancer, business.industry, Incidence (epidemiology), Gastroenterology, Colonoscopy, Context (language use), medicine.disease, Quality of life, Internal medicine, medicine, Economic impact analysis, Activity-based costing, Adverse effect, business, Intensive care medicine
Abstract

Background and aim: Colorectal cancer (CRC) represents the second leading cause of cancer mortality in Europe. Evidence from several scientific studies suggests that screening for the early detection and removal of cancerous lesions can reduce its incidence and mortality and improve patients’ quality of life. The main literature on this topic refers to the American context, which is extremely different from the Italian one. The aim is to propose the results of a cost-effectiveness analysis of a screening program in Italy using as case-study the experience of a CRC screening program started in 2005 in the Province of Ferrara, to determine the full cost of the screening program and to compare the costs-effectiveness of FOBT and colonoscopy. Material and methods: A micro-costing analysis is used to identify and evaluate all the costs involved in each phase of the screening program, following an activity-based costing approach to consider all the activities carried out in the assistance process. The effectiveness of the diagnostic instrument used, FOBT combined with colonoscopy, is valued in terms of early detected lesions and years of life gained. Finally, we use the cost and effectiveness data collected to estimate the costs for year of life gained using a MISCAN-COLON Model. Results: The preliminary results show that, after the screening implementation, a huge number of new cases of hyperplasic polyps, dysplastic adenomas and carcinomas are detected. Moreover, early diagnosis allows the diagnosis of colorectal cancer at the earliest Dukes’ stages. The results of the Model show that the screening program will reduce mortality of 11% and prevent almost 1,100 deaths, with 12,741 years of life gained in a period of time of 30 years. Comparing the costs born in the first wave of the screening with the number of years potentially saved, the model shows that the incremental cost-effectiveness ratio of the program is almost €5,315 for life year. Conclusions: This study shows the economic benefits of the screening program estimated in similar studies conducted in other countries (Sonnenberg, 2000). Besides, the paper highlights the importance of implementing a screening program not only for the effects that prevention can have in clinical terms, but also for the economic impact of such a policy in terms of long-term sustainability of healthcare systems.

Published
2011

49. 732 EFFICACY AND TOLERANCE OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER PROSPECTIVE OPEN LABEL STUDY

Author

G.G. Di Costanzo, G. Raimondo, Mauro Viganò, Evangelista Sagnelli, Giuseppe Mazzella, Miroslava Subic, Grazia Anna Niro, T. Santantonio, Pietro Lampertico, G.B. Gaeta, F. Stefano, Giuseppina Brancaccio, V. Di Marco, Vincenzo Messina, Barbara Testoni, Alfredo Marzano, C. Sava, Massimo Levrero, M. Puoti, Mario Angelico, and L. Cimino

Subjects
medicine.medical_specialty, HBsAg, Hepatology, Tenofovir, business.industry, Urinary system, Renal function, Pharmacology, Gastroenterology, Open label study, Internal medicine, Toxicity, medicine, Dosing, Adverse effect, business, medicine.drug
Abstract

but 28% had reduced urinary phosphate absorption, as assessed by estimated TmPI/GFR, Overall, TDF dosing was reduced or discontinued in 3.3% of the patients because of renal toxicity or other adverse events. Two patients cleared HBsAg and discontinued TDF successfully. Conclusions: TDF suppressed HBV replication in most NUC-naive patients in field practice up to 21 months with few patients showing an impairment of renal function.

Published
2011

50. 414 PEG-INTERFERON PLUS RIBAVIRIN TREATMENT DOES NOT IMPROVE RECURRENCE AFTER RESECTION OR ABLATION OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS: A CASE-CONTROL STUDY

Author

A. Galeota Lanza, M. De Luca, G.G. Di Costanzo, M.T. Tartaglione, F. Lampasi, and R. Tortora

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, Case-control study, Ablation, medicine.disease, Gastroenterology, Resection, Peg interferon, chemistry.chemical_compound, chemistry, Hepatocellular carcinoma, Internal medicine, medicine, business
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results